目前的研究重点是蛋白质-蛋白质相互作用(PPIs)在生物过程中的重要性以及靶向PPIs作为一种新的疾病治疗策略的潜力。具体来说,该研究探讨了与肥胖相关的PPI网络的交叉链接,1型糖尿病(T1DM),和心脏病(CD),这是一个尚未探索的研究领域。该研究旨在了解高度连接蛋白在网络中的作用及其作为药物靶标的潜力。这项研究的方法涉及从NCBI在线基因数据库中检索基因,三种疾病之间的交叉基因(1型糖尿病,肥胖,和心血管)使用Interactivenn,使用NetworkAnalyst确定合适的药物分子,并进行各种生物信息学分析,如通用蛋白质-蛋白质相互作用,拓扑属性分析,根据GO进行功能富集分析,和京都基因和基因组百科全书(KEGG),基因共表达网络,和蛋白质药物以及蛋白质化学相互作用网络。该研究侧重于人类受试者。这项研究的结果鉴定了12个基因[VEGFA(血管内皮生长因子A),白细胞介素6(IL6),MTHFR(亚甲基四氢叶酸还原酶),NPPB(利钠肽B),RAC1(Rac家族小GTP酶1),LMNA(LaminA/C),UGT1A1(UDP-葡糖醛酸基转移酶家族1膜A1),RETN(Resistin),GCG(胰高血糖素),NPPA(利钠肽A),RYR2(Ryanodine受体2),和PRKAG2(蛋白激酶AMP激活的非催化亚基Gamma2)]在三种疾病中共享,可用作蛋白质-药物/化学相互作用的关键蛋白质。此外,这项研究提供了对这三种疾病之间复杂的分子和生物学关系以及导致其发展的细胞机制的深入了解。本研究通过改善治疗效果,突出了对各种疾病的治疗和管理的潜在重大影响。简化治疗方案,成本效益,更好地了解这些疾病的潜在机制,早期诊断,并引入个性化医疗。总之,当前的研究为与肥胖相关的PPI网络的交叉链接提供了新的见解,T1DM,CD,并强调了靶向PPIs作为这些流行疾病的新治疗策略的潜力。
The current study focuses on the importance of Protein-Protein Interactions (PPIs) in biological processes and the potential of targeting PPIs as a new treatment strategy for diseases. Specifically, the study explores the cross-links of PPIs network associated with obesity, type 1 diabetes mellitus (T1DM), and cardiac disease (CD), which is an unexplored area of research. The research aimed to understand the role of highly connected proteins in the network and their potential as drug targets. The methodology for this research involves retrieving genes from the NCBI online gene database, intersecting genes among three diseases (type 1 diabetes, obesity, and cardiovascular) using Interactivenn, determining suitable drug molecules using NetworkAnalyst, and performing various bioinformatics analyses such as Generic Protein-Protein Interactions, topological properties analysis, function enrichment analysis in terms of GO, and Kyoto Encyclopedia of Genes and Genomes (KEGG), gene co-expression network, and protein drug as well as protein chemical interaction network. The study focuses on human subjects. The results of this study identified 12 genes [VEGFA (Vascular Endothelial Growth Factor A), IL6 (Interleukin 6), MTHFR (Methylenetetrahydrofolate reductase), NPPB (Natriuretic Peptide B), RAC1 (Rac Family Small GTPase 1), LMNA (Lamin A/C), UGT1A1 (UDP-glucuronosyltransferase family 1 membrane A1), RETN (Resistin), GCG (Glucagon), NPPA (Natriuretic Peptide A), RYR2 (Ryanodine receptor 2), and PRKAG2 (Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 2)] that were shared across the three diseases and could be used as key proteins for protein-drug/chemical interaction. Additionally, the study provides an in-depth understanding of the complex molecular and biological relationships between the three diseases and the cellular mechanisms that lead to their development. Potentially significant implications for the therapy and management of various disorders are highlighted by the findings of this study by improving treatment efficacy, simplifying treatment regimens, cost-effectiveness, better understanding of the underlying mechanism of these diseases, early diagnosis, and introducing personalized medicine. In conclusion, the current study provides new insights into the cross-links of PPIs network associated with obesity, T1DM, and CD, and highlights the potential of targeting PPIs as a new treatment strategy for these prevalent diseases.